The research demonstrates that CRISPR/Cas9 can selectively switch specific genes on or off, effectively killing prostate cancer cells in both cell cultures and mouse models. What’s particularly promising is that it works in vivo using human xenograft models, which is a solid step toward potential clinical trials in the near future.

Plus, another research team recently made advancements in genetic therapy delivery that bypasses the liver, which often blocks gene therapies. They managed to implant a cow gene into mice, creating “double-muscled” mice with twice the muscle mass. If these methods are combined, we could see some powerful synergies for targeting cancer and improving muscle health!

Source